These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 18440229)

  • 1. 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors.
    Jones P; Bottomley MJ; Carfí A; Cecchetti O; Ferrigno F; Lo Surdo P; Ontoria JM; Rowley M; Scarpelli R; Schultz-Fademrecht C; Steinkühler C
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3456-61. PubMed ID: 18440229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors.
    Scarpelli R; Di Marco A; Ferrigno F; Laufer R; Marcucci I; Muraglia E; Ontoria JM; Rowley M; Serafini S; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6078-82. PubMed ID: 18952417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors.
    Muraglia E; Altamura S; Branca D; Cecchetti O; Ferrigno F; Orsale MV; Palumbi MC; Rowley M; Scarpelli R; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6083-7. PubMed ID: 18930398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors.
    Krennhrubec K; Marshall BL; Hedglin M; Verdin E; Ulrich SM
    Bioorg Med Chem Lett; 2007 May; 17(10):2874-8. PubMed ID: 17346959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
    Jones P; Altamura S; De Francesco R; Paz OG; Kinzel O; Mesiti G; Monteagudo E; Pescatore G; Rowley M; Verdirame M; Steinkühler C
    J Med Chem; 2008 Apr; 51(8):2350-3. PubMed ID: 18370373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases.
    Wang DF; Helquist P; Wiech NL; Wiest O
    J Med Chem; 2005 Nov; 48(22):6936-47. PubMed ID: 16250652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design.
    Suzuki T; Matsuura A; Kouketsu A; Nakagawa H; Miyata N
    Bioorg Med Chem Lett; 2005 Jan; 15(2):331-5. PubMed ID: 15603949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases.
    Bhuiyan MP; Kato T; Okauchi T; Nishino N; Maeda S; Nishino TG; Yoshida M
    Bioorg Med Chem; 2006 May; 14(10):3438-46. PubMed ID: 16439135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.
    Codd R; Braich N; Liu J; Soe CZ; Pakchung AA
    Int J Biochem Cell Biol; 2009 Apr; 41(4):736-9. PubMed ID: 18725319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.
    Shinji C; Maeda S; Imai K; Yoshida M; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2006 Nov; 14(22):7625-51. PubMed ID: 16877001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural origin of selectivity in class II-selective histone deacetylase inhibitors.
    Estiu G; Greenberg E; Harrison CB; Kwiatkowski NP; Mazitschek R; Bradner JE; Wiest O
    J Med Chem; 2008 May; 51(10):2898-906. PubMed ID: 18412327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.
    Finnin MS; Donigian JR; Cohen A; Richon VM; Rifkind RA; Marks PA; Breslow R; Pavletich NP
    Nature; 1999 Sep; 401(6749):188-93. PubMed ID: 10490031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
    Suzuki N; Suzuki T; Ota Y; Nakano T; Kurihara M; Okuda H; Yamori T; Tsumoto H; Nakagawa H; Miyata N
    J Med Chem; 2009 May; 52(9):2909-22. PubMed ID: 19419205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.
    Jones P; Altamura S; De Francesco R; Gallinari P; Lahm A; Neddermann P; Rowley M; Serafini S; Steinkühler C
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1814-9. PubMed ID: 18308563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy.
    Ontoria JM; Altamura S; Di Marco A; Ferrigno F; Laufer R; Muraglia E; Palumbi MC; Rowley M; Scarpelli R; Schultz-Fademrecht C; Serafini S; Steinkühler C; Jones P
    J Med Chem; 2009 Nov; 52(21):6782-9. PubMed ID: 19888759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases.
    Hildmann C; Wegener D; Riester D; Hempel R; Schober A; Merana J; Giurato L; Guccione S; Nielsen TK; Ficner R; Schwienhorst A
    J Biotechnol; 2006 Jun; 124(1):258-70. PubMed ID: 16567013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
    Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of a series of potent and selective ketone histone deacetylase inhibitors.
    Pescatore G; Kinzel O; Attenni B; Cecchetti O; Fiore F; Fonsi M; Rowley M; Schultz-Fademrecht C; Serafini S; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5528-32. PubMed ID: 18809328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of novel histone deacetylase inhibitors.
    Siliphaivanh P; Harrington P; Witter DJ; Otte K; Tempest P; Kattar S; Kral AM; Fleming JC; Deshmukh SV; Harsch A; Secrist PJ; Miller TA
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4619-24. PubMed ID: 17555962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the function of the 14 A long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors.
    Wang DF; Wiest O; Helquist P; Lan-Hargest HY; Wiech NL
    J Med Chem; 2004 Jun; 47(13):3409-17. PubMed ID: 15189037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.